AbbVie's AQUIPTA Wins EU Approval for Acute Migraine Treatment

AbbVie Inc. (NYSE:ABBV) announced on June 2, 2026, that the European Commission has approved AQUIPTA® for the acute treatment of migraine in adults, with or without aura, to be taken as needed. This is the second indication for AQUIPTA in Europe, following its earlier approval for migraine prevention.

The Product

AQUIPTA is an oral CGRP receptor antagonist, targeting a key protein involved in migraine attacks. It offers rapid absorption and efficacy in relieving pain and associated symptoms such as nausea and photophobia.

Pricing and Availability

AbbVie has not yet disclosed pricing or launch timelines for the European market. Pricing will likely be determined through negotiations with national health authorities following EMA assessment.

Competition

AQUIPTA faces competition from other CGRP antagonists like Pfizer's Ubrelvy and Biohaven's Nurtec ODT, as well as traditional triptans. However, its novel mechanism may benefit patients who do not respond to conventional therapies.

Potential Impact on AbbVie

The new approval is expected to boost AbbVie's neurology revenue by expanding the addressable patient population. However, intense competition in the migraine market may temper rapid sales growth.